Selling Your Veterinary Practice to VetEvolve: A Vet’s 2026 Guide

Key takeaways

• VetEvolve is a veterinary practice support platform headquartered in Richmond, Virginia, founded in 2014, operating more than 50 general practice hospitals across the Mid-Atlantic and Southeast as of 2026.
• Varsity Healthcare Partners has owned VetEvolve since 2023, when it acquired the platform from Align Capital Partners. In 2025, VetEvolve appointed Catherine Howell as CEO; co-founder Nick Lodestro, who previously served as CEO, continues to serve on the company’s board.
• The joint-venture partnership model is VetEvolve’s defining feature. The seller keeps the practice name and customer-facing identity inside the partnership and retains a minority equity stake plus a continuing voice, per VetEvolve company materials. Your name stays on the door.
• A partnership where your name stays on the door is a feature, not a guarantee until it is written into the definitive agreement. The leverage point is making the identity promise, the governance voice, and the buyout mechanics specific and enforceable rather than aspirational.
• The most reliable way to know what VetEvolve — or any major buyer — would actually pay for your specific practice, and on what partnership terms, is to run a structured competitive process. We call ours the Elite Selling System: we hand-select and vet every buyer who gets to bid, the way a doorman with a velvet rope lets in only the right people, then run a private bidding window inside that vetted group. VetEvolve is invited inside that rope on practices that fit their footprint, and when they bid against a curated group of qualified competitors, both the number and the partnership terms tend to land very differently than they would in a direct, single-bidder conversation.

When a vet hands me a VetEvolve term sheet, the first thing they usually want to talk about isn’t the number. It’s the sign over the front door.

Most of the consolidator conversations I sit in start with the owner bracing for the day their practice name disappears, replaced by a logo nobody in town recognizes. The VetEvolve conversation starts somewhere else, because the whole pitch is built on the opposite promise: you sell, you take your money, and the name your clients have driven past for 20 years stays exactly where it is.

That promise is the through-line of every VetEvolve discussion. The platform’s signature structure is a joint-venture partnership, which is a deal where the buyer and the selling owner co-own the practice through a shared entity, the seller keeps a minority stake and a continuing voice, and the practice keeps its name and identity.

The emotional pull of “your name stays on the door” is real, and it’s earned. But it also reshapes where the negotiation matters, and that’s the part most owners don’t see coming.

What follows is the same picture I’d lay out over dinner if a vet handed me a VetEvolve offer and asked what to do with it. Who VetEvolve is, how the joint-venture model actually changes the deal, what the partnership means for the name on your building and the equity in your pocket, where the real leverage sits, and how to weigh VetEvolve against the rest of the US veterinary buyer pool in a properly run process.

Quick facts on VetEvolve

VetEvolve was founded in 2014 and has grown from a single hospital into a network of more than 50 general practice veterinary hospitals as of 2026. The platform’s headquarters are in Richmond, Virginia, with its footprint concentrated across the Mid-Atlantic and Southeast.

VetEvolve’s network is built almost entirely on general companion-animal practices rather than specialty or emergency hospitals. The platform’s growth has come through a steady cadence of add-on acquisitions of established multi-doctor and single-doctor practices that fit its regional clusters, per VetEvolve company materials.

The ownership picture has two recent chapters. Align Capital Partners backed VetEvolve starting in 2020 and helped scale the platform from roughly a dozen clinics to more than 30.

In October 2023, Varsity Healthcare Partners completed a strategic growth investment in VetEvolve, acquiring the platform from Align Capital Partners. Varsity Healthcare Partners is a healthcare-focused private equity firm.

In 2025, VetEvolve appointed Catherine Howell as CEO, having previously served as the platform’s chief operating officer and interim CEO; co-founder Nick Lodestro, who led the company as CEO through its earlier growth, continues to serve on the board.

The single most important practical fact for a seller evaluating VetEvolve. The platform’s defining structure is a joint-venture partnership where the practice keeps its name and the owner keeps a stake. That is structurally different from a buyer whose model is 100-percent acquisition with a rebrand, and different again from a buyer who takes 100 percent but offers a passive rollover into a holding company. With VetEvolve, the identity stays local and the owner stays in the room.

The implication runs in both directions, because a continuing partnership is only as good as the terms that govern it.

What VetEvolve actually pays for veterinary practices in 2026

The consistent pattern we see. When a multi-doctor practice receives a direct offer from any major buyer’s acquisition team — VetEvolve included — the offer reflects the leverage the buyer perceives in the conversation. A single bidder facing no visible competition has no structural reason to put forward their strongest valuation, their most favorable partnership split, or their most explicit name-and-identity guarantees in the first conversation.

Inside a properly structured competitive process, where the buyer knows other qualified bidders are underwriting the same practice in parallel, those dimensions tend to move, sometimes meaningfully. The pattern is not unique to VetEvolve.

It is the basic dynamic of how every major buyer in this market calibrates an offer to the room.

VetEvolve does not publish a standard price sheet for any specific practice profile. Per industry M&A commentary (Octus, Capstone Partners, 2025-2026), competitive outcomes for strong multi-doctor general practices in the $2 million-plus revenue range tend to land in the low-teens EBITDA range across the major buyer pool.

EBITDA is what your practice earns in pure operating profit, before taxes and accounting choices, and the multiple is the multiplier buyers apply to that profit to set the price. The actual number for any specific practice depends heavily on whether other buyers are at the table and the specific profile of the practice.

There’s a wrinkle specific to the joint-venture structure that owners need to understand. In a partnership, the headline number and the cash you actually pocket are not the same thing. When you keep a minority stake, a portion of your practice value is converted into retained equity rather than cash at close. That can be a feature, because the retained slice can grow and pay out again at the platform’s exit.

But it means a VetEvolve partnership offer has to be read as two numbers — the cash today and the value of the equity you’re keeping — not one.

For larger multi-location groups ($10 million-plus revenue, $2 million-plus EBITDA), the multiple range typically extends higher than for single-location practices, with deal sizes scaling into the eight-figure-plus range. VetEvolve has historically focused on general practices that fit its regional clusters rather than large specialty platforms, so the very largest multi-location specialty groups may sit outside its core target profile.

For practices below the $2 million revenue threshold or single-doctor practices in markets outside VetEvolve’s clusters, the buyer pool generally shifts toward regional PE-backed groups, smaller consolidators, and individual buyers. VetEvolve’s footprint density in the Mid-Atlantic and Southeast means a practice’s geographic fit matters as much as its size.

The cash-at-close reality

In a 100-percent acquisition, the cash-at-close conversation is straightforward: the majority of the deal value lands in your account at closing, and the rest sits in earnout and any rollover. A joint-venture partnership reshapes that math, because the structure is built around the seller keeping a slice rather than cashing out fully.

Per industry M&A commentary across the major buyer pool (Dechert LLP, Holland & Knight, Capstone Partners 2025-2026), partnership structures commonly pay the seller liquidity on the majority of the practice value at close, with the remainder converted into retained equity in the joint venture. Rollover equity means keeping a slice of ownership in the new entity instead of taking all cash at close.

VetEvolve’s specific split on any given deal is negotiated case by case under confidentiality.

The key question a seller has to answer with a VetEvolve partnership offer is how much of the headline value is cash and how much is retained stake — and what that retained stake is actually worth. The retained slice rides the future growth of the practice and the platform, and it pays out again when VetEvolve itself sells.

VetEvolve has already been through one PE-ownership transition, from Align Capital Partners to Varsity Healthcare Partners in 2023, which gives a rollover investor some documented platform history to underwrite rather than a purely hypothetical future exit. That doesn’t set the formula price in any specific deal, but it does give the retained-equity conversation more grounding than a brand-new platform could offer.

A note on deal structure types in the current market

The broader US veterinary M&A market has shifted measurably toward partnership and joint-venture structures over the past 18 months, per MB Law Firm’s 2025 healthcare M&A commentary. VetEvolve sits at the leading edge of that shift, because the joint-venture partnership is its headline structure rather than an occasional option.

In a typical veterinary joint-venture partnership, the buyer takes a majority stake, the seller retains a minority stake as direct equity, and a contractual put/call mechanism defines the buyout date and formula price for the retained equity. The put/call is simply the agreed mechanism and timing for the seller to sell, and the buyer to buy, the retained stake down the road.

VetEvolve formalized this approach with its first named joint-venture partnerships in 2026, including practices that joined as the platform’s growth crossed the 50-practice mark, per VetEvolve and Varsity Healthcare Partners materials.

What makes VetEvolve’s version distinctive is the explicit pairing of the partnership with name-and-identity preservation. Per VetEvolve company materials, practices that join continue to operate under their established names and identities, with clinical leadership preserved.

The structure is pitched at owners who want liquidity now, continued upside through the retained stake, and the local identity their clients know — all at once. Sellers evaluating a VetEvolve offer should ask explicitly how the retained-equity slice is valued, when and how it can be bought out, and exactly what governance voice comes with it.

Our PE pricing guide covers the structure-by-structure comparison in depth.

How VetEvolve’s acquisition team operates

VetEvolve’s corporate-development team sources practices the way most regional platforms do, but with a sharper geographic filter. The team emphasizes practices in the Mid-Atlantic and Southeast markets where VetEvolve already has density, per VetEvolve company materials, because referral relationships, shared back-office support, and recruiting reach are all easier to deliver when a new practice sits inside an existing regional cluster.

The team works the standard mix of channels: direct outreach to owners identified through industry data and broker relationships, participation in structured competitive sale processes run by qualified sell-side advisors, and inbound inquiries from owners reaching out on their own.

A practical implication for sellers. Because the joint-venture partnership is VetEvolve’s signature pitch, the team tends to lead with the relationship and the identity-preservation story rather than the headline number.

That’s genuinely attractive, and it’s also exactly why a seller needs an outside read on the economics. The same partnership story sounds compelling whether the underlying valuation is strong or merely adequate.

The VetEvolve team, like every institutional buyer, engages more substantively and competes harder on terms when the deal materials they receive reflect a sophisticated sell-side process rather than a casual one-on-one conversation.

How VetEvolve integrates the practices it acquires

VetEvolve’s integration model is, by design, the lightest-touch end of the consolidator spectrum on the dimension that owners care about most — the customer-facing identity stays put.

Name and identity preservation. Per VetEvolve company materials, practices that join VetEvolve continue to operate under their established names and identities, and the joint-venture model explicitly preserves clinical leadership. This is the heart of the VetEvolve proposition.

The sign stays up, the website stays branded to the local practice, and the clients who have come for years see continuity rather than a corporate rebrand. This is one of the dimensions where VetEvolve differs structurally from Mars-affiliated entities, which more commonly transition acquired practices to a Mars-network brand over time.

Shared operational support. Per VetEvolve company materials, the platform provides the back-office infrastructure that independent practices struggle to build alone — recruiting and HR, accounting and payroll, vendor and supply purchasing, marketing infrastructure, and operational systems. The stated goal of the partnership model is to support continued investment in people, facilities, and systems while preserving the owner’s voice and accountability.

Centralized procurement. Platform scale translates into purchasing leverage that most independent practices cannot match. VetEvolve’s negotiated vendor contracts for diagnostics, pharmaceuticals, equipment, and supplies typically reduce variable costs across the practice’s P&L compared with the independent baseline.

In a joint-venture structure this cuts both ways, because the seller still owns a slice of the practice — so procurement gains can lift the value of the retained stake, while procurement decisions that override local preferences need protective language in the partnership agreement.

Owner voice and clinical leadership. The distinguishing claim of the joint-venture model is that the selling owner keeps a real seat at the table rather than becoming a salaried employee with no say. Per VetEvolve company materials, the model is designed to align clinical leadership with enterprise performance while preserving owner accountability.

The substance behind that claim lives entirely in the governance terms of the definitive agreement, which is why those terms are where the negotiation effort belongs.

Doctor relationships. Per industry M&A commentary on PE-backed veterinary acquirers, selling owners in partnership structures commonly stay on in a continuing clinical and leadership role for a multi-year period, with compensation structured as base salary plus production bonus alongside the retained equity. VetEvolve’s specific post-sale role and compensation terms for any given deal are negotiated case by case under the definitive partnership agreement.

VetEvolve’s recent activity in 2025-2026

VetEvolve enters 2026 as an active, growing acquirer concentrated in the Mid-Atlantic and Southeast. Capstone Partners‘ April 2026 Pet Sector M&A Update documents the broader sector acceleration heading into Q1 2026, with both PE-backed and strategic acquirers running active pipelines.

VetEvolve’s own 2026 milestones include the formalization of named joint-venture partnerships, including practices that joined as the network passed 50 hospitals, per VetEvolve and Varsity Healthcare Partners materials.

The practical takeaway for an owner receiving 2026 VetEvolve outreach: this is a buyer leaning into the partnership model as its growth engine, actively expanding its joint-venture footprint, and selective about geographic fit. The implications of that focus — the genuine identity preservation, the retained-equity upside, and the governance terms that determine whether the partnership actually serves the seller — are the lens through which the offer in your hand should be evaluated.

Have an offer from VetEvolve? Get a Free Practice Value Estimate — send us the offer and we’ll decompose the partnership terms, separate the cash from the retained equity, identify what’s typically negotiable, and project what your practice would likely clear in a structured competitive process with the broader qualified buyer pool. No upfront cost, no obligation.

How VetEvolve compares to the other major buyers

If you’re considering VetEvolve, you’re probably comparing them implicitly to the other buyers who would compete for your practice. Here’s how VetEvolve stacks up across the dimensions that matter, with the partnership-and-identity lens front and center.

Versus Mars Veterinary Health (VCA, BluePearl, Banfield). Mars is the strategic family-owned exception in the US veterinary buyer pool per Mars company disclosures, distinguishing it from VetEvolve’s PE-backed structure. The contrast on identity is stark: VetEvolve’s joint-venture model keeps the local name and gives the owner a continuing stake, while VCA has historically transitioned acquired practices toward the VCA brand over time.

Both may compete for qualifying practices in a structured sale process. Our Mars Veterinary Health buyer profile covers the Mars-specific dimensions in depth.

Versus NVA (JAB Holdings). NVA is owned by JAB Holdings, a privately held long-hold investment vehicle distinguishable from PE-fund-cycle ownership. Both NVA and VetEvolve preserve local practice branding per their respective company materials.

The key difference is structural: NVA’s model centers on local brand preservation under a long-hold owner, while VetEvolve’s centers on a joint-venture partnership where the owner keeps both the name and a continuing equity stake. Our NVA buyer profile walks through the NVA-specific dimensions.

Versus AmeriVet Veterinary Partners. AmeriVet has publicly emphasized partnership and JV structures with dual-sponsor PE backing, which puts it in the closest competitive lane to VetEvolve on structure. Both preserve local brand identity and offer retained equity per their respective company materials.

The choice often comes down to footprint fit and the specific governance and buyout terms each platform offers inside its partnership. Our AmeriVet buyer profile covers the partnership-model dimensions.

Versus VetCor (Harvest Partners). VetCor is one of the longest-tenured PE-backed platforms and also preserves local branding, but its standard posture leans toward 100-percent acquisition with rollover equity rather than a co-ownership joint venture. The choice between them often comes down to whether the seller wants a true partnership seat (VetEvolve) or a traditional rollover into a deeper, longer-tenured platform (VetCor).

Our VetCor buyer profile covers the institutional-depth dimensions.

Versus the smaller and regional PE-backed groups (Thrive Pet Healthcare, Alliance Animal Health, Heartland, VPP, others). Each has its own structure and target profile, and several offer partnership or co-ownership variants of their own. Smaller and newer groups sometimes compete aggressively for practices that fill specific geographic gaps.

The right way to evaluate which buyer offers the best combination of value and partnership terms is to put all of them in a competitive process and let them surface their best offers in parallel.

What to negotiate before signing with VetEvolve

Six priorities when negotiating a VetEvolve joint-venture partnership, with the partnership-and-identity terms as the highest-leverage category given that the entire VetEvolve proposition rests on them.

The name-and-identity commitment in writing (highest priority). VetEvolve’s whole pitch is that your name stays on the door. But marketing-page language about preserving identity is not the same as a binding clause.

Negotiate explicit, contractual name-and-identity protection: the practice name, signage, website, and local marketing identity preserved for a defined period or indefinitely, with clear limits on any future rebrand. Get the promise that drew you to VetEvolve written into the definitive agreement.

Governance and owner voice. The joint-venture model promises you keep a seat at the table. Make that seat real.

Negotiate specific governance rights — information rights, consent rights over major decisions affecting the practice, clear definition of which decisions stay local versus migrating to the platform, and minority-protection provisions. A “voice” with no defined rights behind it is a courtesy, not a protection.

The retained-equity terms. Your minority stake is a meaningful chunk of your total value, so the terms governing it matter as much as the cash. Negotiate how the retained equity is valued today, the put/call mechanism that defines when and how you can sell it later, the formula price for that buyout, anti-dilution provisions, and your information rights as a continuing equity holder.

Cash at close versus retained stake. Decide deliberately how much of your value you want as guaranteed cash now versus retained equity riding the platform’s future. Push for the cash percentage that fits your risk tolerance and timeline.

Every dollar in cash at close is certain money; every dollar in retained equity is upside that depends on the platform’s future performance and exit.

Post-sale role and compensation. Negotiate your continuing clinical and leadership role, the base-salary-plus-production-bonus formula, and the term of your commitment. Make sure the role you’re signing up for matches the “owner voice” the partnership promised, rather than collapsing into a salaried position once the ink dries.

Non-compete scope. Non-competes commonly run several years and cover a defined geographic radius. Negotiate shorter duration (1 to 2 years), a tighter radius (5 to 10 miles), or carve-outs for specific work you might continue.

In a partnership where you keep a stake, the non-compete interacts with your exit options, so read it against the buyout mechanics.

The name-on-the-door question, in depth

For sellers drawn to VetEvolve specifically, the most useful frame is to think hard about what “your name stays on the door” really delivers — and what makes it durable rather than aspirational.

The case for the partnership-and-identity model. When the structure works as pitched, it solves the exact fear that keeps owners from selling at all:

• The practice keeps the name and identity clients have trusted for years, so the goodwill the owner built doesn’t evaporate at closing
• The owner keeps a real equity stake, so a portion of the proceeds rides the future growth rather than being capped at the close-date value
• The retained stake can pay out a second time when the platform exits, which has already happened once for VetEvolve in the 2023 Align-to-Varsity transition
• The owner keeps a defined voice in how the practice runs, rather than handing the keys to a regional operations team
• The platform supplies the back-office, recruiting, and purchasing scale that an independent practice struggles to build, while the local face of the practice stays intact

The case for treating the partnership as a negotiation surface, not a guarantee. The flip side is that every one of those benefits lives in the contract terms, and a partnership pitched warmly can still be governed thinly:

• “Practices continue to operate under their established names” is a stated approach until it’s a binding clause with defined limits on future rebrand
• An “owner voice” with no enumerated consent or information rights is a courtesy that can quietly erode
• The retained-equity value depends entirely on the valuation formula, the buyout timing, and anti-dilution terms — all negotiable, all defaulted in the platform’s favor absent pushback
• The post-sale role can drift from “partner with a seat at the table” toward “salaried medical director” if the role and governance aren’t pinned down
• The platform’s procurement and operational decisions affect the value of the very stake the seller is keeping

The balance between the promise and the protections is exactly what gets negotiated in the definitive partnership agreement. Sellers who go in with a refined sell-side process — and other qualified bidders at the table — consistently land more enforceable identity protections, sharper governance rights, and better retained-equity terms than sellers who engage in a one-on-one conversation built on the warmth of the pitch.

Should I take a VetEvolve offer or run a competitive process?

For VetEvolve specifically, the value of the competitive process is concentrated in two places: the total economics of the partnership, and the enforceability of the terms that make “your name stays on the door” real. A direct, single-bidder VetEvolve conversation gives you the pitch and a number.

It doesn’t tell you whether another qualified buyer would value your practice higher, offer a better cash-to-equity split, or write stronger identity and governance protections into the agreement.

The mechanical reason is the same as for any major buyer. Without competition, no buyer has incentive to soften the pre-set defaults in their standard partnership template or to sharpen the valuation.

With competition, every term becomes negotiable, because every bidder knows the seller has alternatives. For a partnership-led platform like VetEvolve, where the emotional appeal of the structure can overshadow the underlying economics, the leverage a structured process produces is particularly valuable.

VetEvolve participates in well-run competitive processes when invited and when the practice fits its footprint. The VetEvolve-specific dimensions — the name-and-identity clause, the governance and voice provisions, the cash-versus-retained-equity split, the buyout formula and timing — get sharper attention from the VetEvolve team when they know other qualified buyers are at the table on the same practice in the same window.

What our Elite Selling System actually does

For a VetEvolve-affiliated transaction, our process runs differently than it does for a 100-percent-acquisition buyer, because the negotiation surface lives inside the partnership terms and the identity commitments rather than only in the headline multiple.

Phase one — the partnership-term audit. Before any bidder packet goes out, we deconstruct the VetEvolve joint-venture template against the comparable partnership templates we’ve seen from the rest of the buyer pool. How is the retained equity valued, and against what formula?

What governance rights actually come with the owner’s “voice,” and what’s missing? What does the name-and-identity language commit to in writing, and where can it be strengthened?

What does the buyout put/call mechanism default to? This audit surfaces the leverage points before the competitive process opens.

Phase two — the bidder mix. From the 42-plus named veterinary consolidators TE actively tracks, we invite only the ones that legitimately compete with VetEvolve for this specific practice. The partnership-and-identity buyers (AmeriVet, the regional PE-backed groups with explicit co-ownership models) are natural competitors on the structure VetEvolve leads with.

The brand-preservation buyers (NVA, VetCor) compete on the name-on-the-door promise through a different structure. The strategic family-owned alternative (Mars, where the practice fits Mars’s criteria) competes on long-hold posture.

The right mix is typically 5 to 7 invited bidders, each genuinely competing on a dimension a VetEvolve seller cares about.

Phase three — the term-by-term comparison. Bidders return their full term sheets, not just the headline numbers. The seller sees side-by-side comparisons across cash at close, retained-equity value and buyout terms, partnership governance and owner voice, name-and-identity commitments, post-sale role, non-compete scope, and integration approach.

The seller chooses on the dimensions that matter — sometimes the platform with the strongest identity guarantee (often VetEvolve’s natural strength), sometimes the platform with the highest cash number, sometimes the one with the best retained-equity upside.

The economic result holds across deal types: practices in the qualifying revenue band that run our process consistently clear materially better total economic outcomes — typically multiple seven figures, sometimes more — than the same practice would have cleared by signing the original direct VetEvolve term sheet without testing the field, and with stronger written protections on the partnership terms that made the deal attractive in the first place.

Closing thought

The honest read on VetEvolve: it offers one of the more genuinely owner-friendly propositions in the US veterinary buyer pool. Your name stays on the door, you keep a real equity stake and a continuing voice, and you take meaningful liquidity now.

For an owner who has spent decades building a local identity and can’t stomach watching it disappear under a corporate logo, that’s a compelling answer to the fear that keeps a lot of good practices off the market.

What separates a well-negotiated VetEvolve outcome from a mediocre one isn’t whether the pitch is appealing — it almost always is — but whether the promises behind it are written into the agreement. The name-and-identity clause, the governance and voice provisions, the retained-equity valuation and buyout mechanics.

Those terms decide whether “your name stays on the door” is a binding commitment or a warm sentiment, and whether your retained stake is real upside or a soft number.

If you’ve received a VetEvolve offer, or if VetEvolve’s team has reached out to start the partnership conversation, the highest-leverage move is to understand how the rest of the field would value your practice and structure the same partnership before committing to anything. Get a Free Practice Value Estimate and we’ll lay out the same partnership-term comparison we would for a client across a dinner table.

Sources

Industry M&A research and valuation data

1. Capstone Partners. Pet Sector M&A Update — April 2026. Capstone Partners industry research.
2. Octus. Veterinary Services Roll-Up Coverage, 2025-2026. Octus credit research and industry commentary.
3. Dechert LLP. Healthcare M&A: 2025-2026 Trends and Outlook. Dechert healthcare practice publications.
4. Holland & Knight. Healthcare Private Equity 2025-2026 Commentary. Holland & Knight healthcare practice publications.
5. MB Law Firm. 2025 Healthcare M&A Trends — Joint Venture and Partnership Structures. MB Law Firm healthcare publications.

VetEvolve and parent company materials

6. VetEvolve. About VetEvolve, partnership benefits, and joint-venture model. VetEvolve company materials, 2024-2026. vetevolve.com
7. Varsity Healthcare Partners. Varsity Healthcare Partners Completes Strategic Growth Investment in VetEvolve (October 2023) and VetEvolve Expands Mid-Atlantic Footprint with First Joint Venture Partnership (2026). varsityhealthcarepartners.com
8. Lincoln International. Align Capital Partners has sold VetEvolve to Varsity Healthcare Partners. Lincoln International transaction announcement, 2023. lincolninternational.com

Veterinary practice operations, benchmarks, and profession data

9. iVET360. State of the Veterinary Industry — 2026 Industry Report. iVET360 industry research.
10. American Veterinary Medical Association (AVMA). 2026 AVMA Veterinary Economic Report. AVMA economic research.
11. American Animal Hospital Association (AAHA). Practice valuation and ownership transition resources. AAHA, 2025-2026.